COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC.Common Stock Purchase Warrant • August 27th, 2019 • Seelos Therapeutics, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, _____________ or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after February 27, 2020 (the "Initial Exercise Date") and on or prior to 5:00 p.m. (New York City time) on August 28, 2023 (the "Termination Date") but not thereafter, to subscribe for and purchase from Seelos Therapeutics, Inc., a Nevada corporation (the "Company"), up to ______ shares (as subject to adjustment hereunder, the "Warrant Shares") of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 27th, 2019 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this "Agreement") is dated as of August 23, 2019, between Seelos Therapeutics, Inc., a Nevada corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "Purchaser" and collectively the "Purchasers").
PLACEMENT AGENCY AGREEMENT August 23, 2019Placement Agency Agreement • August 27th, 2019 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
Introduction. Subject to the terms and conditions herein (this "Agreement"), Seelos Therapeutics, Inc., a Nevada corporation (the "Company"), hereby agrees to sell up to an aggregate of $6,712,500 of securities of the Company, including, but not limited to, 4,475,000 registered shares (the "Shares") of the Company's common stock, $0.001 par value per share (the "Common Stock"), and unregistered Common Stock purchase warrants to purchase up to an aggregate of 2,237,500 shares of Common Stock (the "Warrants" and the shares of Common Stock issuable upon exercise of the Warrants, the "Warrant Shares") (the Shares, Warrants and Warrant Shares, collectively, the "Securities") directly to various investors (each, an "Investor" and, collectively, the "Investors") through Roth Capital Partners, LLC (the "Placement Agent") as placement agent. The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including, without limitation, a
LEAK-OUT AGREEMENTLeak-Out Agreement • August 27th, 2019 • Seelos Therapeutics, Inc. • Pharmaceutical preparations
This agreement (the "Leak-Out Agreement") is being delivered to you in connection with an understanding by and between Seelos Therapeutics, Inc., a Nevada corporation (the "Company"), and the person or persons named on the signature pages hereto (collectively, the "Holder").
